326 related articles for article (PubMed ID: 25972510)
1. Aberrant glomerular filtration of urokinase-type plasminogen activator in nephrotic syndrome leads to amiloride-sensitive plasminogen activation in urine.
Stæhr M; Buhl KB; Andersen RF; Svenningsen P; Nielsen F; Hinrichs GR; Bistrup C; Jensen BL
Am J Physiol Renal Physiol; 2015 Aug; 309(3):F235-41. PubMed ID: 25972510
[TBL] [Abstract][Full Text] [Related]
2. Urokinase-type plasminogen activator contributes to amiloride-sensitive sodium retention in nephrotic range glomerular proteinuria in mice.
Hinrichs GR; Weyer K; Friis UG; Svenningsen P; Lund IK; Nielsen R; Mollet G; Antignac C; Bistrup C; Jensen BL; Birn H
Acta Physiol (Oxf); 2019 Dec; 227(4):e13362. PubMed ID: 31423748
[TBL] [Abstract][Full Text] [Related]
3. Urokinase-type plasminogen activator (uPA) is not essential for epithelial sodium channel (ENaC)-mediated sodium retention in experimental nephrotic syndrome.
Bohnert BN; Daiminger S; Wörn M; Sure F; Staudner T; Ilyaskin AV; Batbouta F; Janessa A; Schneider JC; Essigke D; Kanse S; Haerteis S; Korbmacher C; Artunc F
Acta Physiol (Oxf); 2019 Dec; 227(4):e13286. PubMed ID: 31006168
[TBL] [Abstract][Full Text] [Related]
4. Amiloride: the "new" renal tonic?
Warnock DG
Am J Physiol Renal Physiol; 2015 Sep; 309(5):F429-30. PubMed ID: 26084931
[No Abstract] [Full Text] [Related]
5. Mechanisms of renal NaCl retention in proteinuric disease.
Svenningsen P; Friis UG; Versland JB; Buhl KB; Møller Frederiksen B; Andersen H; Zachar RM; Bistrup C; Skøtt O; Jørgensen JS; Andersen RF; Jensen BL
Acta Physiol (Oxf); 2013 Mar; 207(3):536-45. PubMed ID: 23216619
[TBL] [Abstract][Full Text] [Related]
6. Amiloride Reduces Urokinase/Plasminogen-Driven Intratubular Complement Activation in Glomerular Proteinuria.
Isaksson GL; Hinrichs GR; Andersen H; Bach ML; Weyer K; Zachar R; Henriksen JE; Madsen K; Lund IK; Mollet G; Bistrup C; Birn H; Jensen BL; Palarasah Y
J Am Soc Nephrol; 2024 Apr; 35(4):410-425. PubMed ID: 38254266
[TBL] [Abstract][Full Text] [Related]
7. Amiloride lowers blood pressure and attenuates urine plasminogen activation in patients with treatment-resistant hypertension.
Oxlund CS; Buhl KB; Jacobsen IA; Hansen MR; Gram J; Henriksen JE; Schousboe K; Tarnow L; Jensen BL
J Am Soc Hypertens; 2014 Dec; 8(12):872-81. PubMed ID: 25492830
[TBL] [Abstract][Full Text] [Related]
8. Plasmin in nephrotic urine activates the epithelial sodium channel.
Svenningsen P; Bistrup C; Friis UG; Bertog M; Haerteis S; Krueger B; Stubbe J; Jensen ON; Thiesson HC; Uhrenholt TR; Jespersen B; Jensen BL; Korbmacher C; Skøtt O
J Am Soc Nephrol; 2009 Feb; 20(2):299-310. PubMed ID: 19073825
[TBL] [Abstract][Full Text] [Related]
9. Nephrotic syndrome is associated with increased plasma K
Ydegaard R; Svenningsen P; Bistrup C; Andersen RF; Stubbe J; Buhl KB; Marcussen N; Hinrichs GR; Iraqi H; Zamani R; Dimke H; Jensen BL
Am J Physiol Renal Physiol; 2019 Dec; 317(6):F1549-F1562. PubMed ID: 31566427
[TBL] [Abstract][Full Text] [Related]
10. Remission of nephrotic syndrome diminishes urinary plasmin content and abolishes activation of ENaC.
Andersen RF; Buhl KB; Jensen BL; Svenningsen P; Friis UG; Jespersen B; Rittig S
Pediatr Nephrol; 2013 Aug; 28(8):1227-34. PubMed ID: 23503750
[TBL] [Abstract][Full Text] [Related]
11. Significant natriuretic and antihypertensive action of the epithelial sodium channel blocker amiloride in diabetic patients with and without nephropathy.
Andersen H; Hansen PB; Bistrup C; Nielsen F; Henriksen JE; Jensen BL
J Hypertens; 2016 Aug; 34(8):1621-9. PubMed ID: 27214087
[TBL] [Abstract][Full Text] [Related]
12. Proteinuric diseases with sodium retention: Is plasmin the link?
Svenningsen P; Skøtt O; Jensen BL
Clin Exp Pharmacol Physiol; 2012 Jan; 39(1):117-24. PubMed ID: 21466573
[TBL] [Abstract][Full Text] [Related]
13. Regulation of epithelial sodium channel in puromycin aminonucleoside-induced unilateral experimental nephrotic syndrome in normal and analbuminemic Nagase rats.
Yu Z; Schumacher M; Frey BM; Frey FJ; Vogt B
Nephron Physiol; 2005; 101(3):p51-62. PubMed ID: 16020936
[TBL] [Abstract][Full Text] [Related]
14. Association of Urinary Plasminogen-Plasmin with Edema and Epithelial Sodium Channel Activation in Patients with Nephrotic Syndrome.
Chen JL; Wang L; Yao XM; Zang YJ; Wang Y; Li ZJ; Pearce D; Wang H
Am J Nephrol; 2019; 50(2):92-104. PubMed ID: 31269481
[TBL] [Abstract][Full Text] [Related]
15. Aprotinin prevents proteolytic epithelial sodium channel (ENaC) activation and volume retention in nephrotic syndrome.
Bohnert BN; Menacher M; Janessa A; Wörn M; Schork A; Daiminger S; Kalbacher H; Häring HU; Daniel C; Amann K; Sure F; Bertog M; Haerteis S; Korbmacher C; Artunc F
Kidney Int; 2018 Jan; 93(1):159-172. PubMed ID: 29042083
[TBL] [Abstract][Full Text] [Related]
16. Cathepsin B increases ENaC activity leading to hypertension early in nephrotic syndrome.
Larionov A; Dahlke E; Kunke M; Zanon Rodriguez L; Schiessl IM; Magnin JL; Kern U; Alli AA; Mollet G; Schilling O; Castrop H; Theilig F
J Cell Mol Med; 2019 Oct; 23(10):6543-6553. PubMed ID: 31368174
[TBL] [Abstract][Full Text] [Related]
17. Epithelial sodium channel (ENaC) subunit mRNA and protein expression in rats with puromycin aminonucleoside-induced nephrotic syndrome.
Audigé A; Yu ZR; Frey BM; Uehlinger DE; Frey FJ; Vogt B
Clin Sci (Lond); 2003 Apr; 104(4):389-95. PubMed ID: 12653683
[TBL] [Abstract][Full Text] [Related]
18. Plasminogenuria is associated with podocyte injury, edema, and kidney dysfunction in incident glomerular disease.
Egerman MA; Wong JS; Runxia T; Mosoyan G; Chauhan K; Reyes-Bahamonde J; Anandakrishnan N; Wong NJ; Bagiella E; Salem F; Meliambro K; Li H; Azeloglu EU; Coca SG; Campbell KN; Raij L
FASEB J; 2020 Dec; 34(12):16191-16204. PubMed ID: 33070369
[TBL] [Abstract][Full Text] [Related]
19. Screening bioactive compounds from Danggui-shaoyao-san for treating sodium retention in nephrotic syndrome using bio-affinity ultrafiltration.
Yang M; Ni L; Wang Y; Xuan Z; Wu H; Zhan W; Wan X; Wang J; Xu F
J Ethnopharmacol; 2022 Jun; 292():115171. PubMed ID: 35259444
[TBL] [Abstract][Full Text] [Related]
20. Plasmin in urine from patients with type 2 diabetes and treatment-resistant hypertension activates ENaC in vitro.
Buhl KB; Oxlund CS; Friis UG; Svenningsen P; Bistrup C; Jacobsen IA; Jensen BL
J Hypertens; 2014 Aug; 32(8):1672-7; discussion 1677. PubMed ID: 24805959
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
